Drug Approval | March 28, 2022
EU approves Evusheld to prevent Covid-19
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Registration is open for the global event that invites technology enthusiasts to bring innovative ideas to improve healthcare outcomes
The MoU proposed investments in hospitals, pharmacies and laboratories in the state
The implementation of ScienceMedia's solutions will ultimately help AMCR collapse patient recruitment and enrollment
These courses are for pre-selected candidates who have completed their MBBS with an additional 2 years of surgical experience training
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Subscribe To Our Newsletter & Stay Updated
